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Abstract
The CONSORT statement is used worldwide to improve the reporting of randomised controlled trials. Kenneth Schulz 
and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new 
methodological evidence and accumulating experience.
To encourage dissemination of the CONSORT 2010 Statement, this article is freely accessible on bmj.com and will also 
be published in the Lancet, Obstetrics and Gynecology, PLoS Medicine, Annals of Internal Medicine, Open Medicine, 
Journal of Clinical Epidemiology, BMC Medicine, and Trials.
Introduction
Randomised controlled trials, when appropriately
designed, conducted, and reported, represent the gold
standard in evaluating healthcare interventions. How-
ever, randomised trials can yield biased results if they lack
methodological rigour [1]. To assess a trial accurately,
readers of a published report need complete, clear, and
transparent information on its methodology and find-
ings. Unfortunately, attempted assessments frequently
fail because authors of many trial reports neglect to pro-
vide lucid and complete descriptions of that critical infor-
mation [2-4].
T h a t  la c k  o f  a d eq u a t e  r e po rt i n g  fu e l l ed  t h e  d ev e l o p -
ment of the original CONSORT (Consolidated Standards
of Reporting Trials) statement in 1996 [5] and its revision
five years later [6-8]. While those statements improved
the reporting quality for some randomised controlled tri-
als, [9,10] many trial reports still remain inadequate [2].
Furthermore, new methodological evidence and addi-
tional experience has accumulated since the last revision
in 2001. Consequently, we organised a CONSORT Group
meeting to update the 2001 statement [6-8]. We intro-
duce here the result of that process, CONSORT 2010.
Intent of CONSORT 2010
The CONSORT 2010 Statement is this paper including
the 25 item checklist in the table (Table 1) and the flow
diagram (Figure 1). It provides guidance for reporting all
randomised controlled trials, but focuses on the most
common design type-individually randomised, two
group, parallel trials. Other trial designs, such as cluster
randomised trials and non-inferiority trials, require vary-
ing amounts of additional information. CONSORT
extensions for these designs, [11,12] and other CON-
SORT products, can be found through the CONSORT
website http://www.consort-statement.org. Along with
the CONSORT statement, we have updated the explana-
tion and elaboration article, [13] which explains the inclu-
sion of each checklist item, provides methodological
background, and gives published examples of transparent
reporting.
Diligent adherence by authors to the checklist items
facilitates clarity, completeness, and transparency of
reporting. Explicit descriptions, not ambiguity or omis-
sion, best serve the interests of all readers. Note that the
CONSORT 2010 Statement does not include recommen-
dations for designing, conducting, and analysing trials. It
solely addresses the reporting of what was done and what
was found.
Nevertheless, CONSORT does indirectly affect design
and conduct. Transparent reporting reveals deficiencies
in research if they exist. Thus, investigators who conduct
inadequate trials, but who must transparently report,
should not be able to pass through the publication pro-
cess without revelation of their trial's inadequacies. That
emerging reality should provide impetus to improved
trial design and conduct in the future, a secondary indi-
rect goal of our work. Moreover, CONSORT can help
researchers in designing their trial.
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Table 1: CONSORT 2010 checklist of information to include when reporting a randomised trial*
Section/Topic Item No Checklist item Reported on page No
Title and abstract
1a Identification as a randomised 
trial in the title
1b Structured summary of trial 
design, methods, results, and 
conclusions (for specific 
guidance see CONSORT for 
abstracts [21,31])
Introduction
Background and objectives 2a Scientific background and 
explanation of rationale
2b Specific objectives or 
hypotheses
Methods
Trial design 3a Description of trial design 
(such as parallel, factorial) 
including allocation ratio
3b Important changes to 
methods after trial 
commencement (such as 
eligibility criteria), with 
reasons
Participants 4a Eligibility criteria for 
participants
4b Settings and locations where 
the data were collected
Interventions 5 The interventions for each 
group with sufficient details to 
allow replication, including 
how and when they were 
actually administered
Outcomes 6a Completely defined pre-
specified primary and 
secondary outcome 
measures, including how and 
when they were assessed
6b Any changes to trial outcomes 
after the trial commenced, 
with reasons
Sample size 7a How sample size was 
determined
7b When applicable, explanation 
of any interim analyses and 
stopping guidelines
Randomisation:
Sequence generation 8a Method used to generate the 
random allocation sequence
8b Type of randomisation; details 
of any restriction (such as 
blocking and block size)Schulz et al. BMC Medicine 2010, 8:18
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Allocation concealment 
mechanism
9 Mechanism used to 
implement the random 
allocation sequence (such as 
sequentially numbered 
containers), describing any 
steps taken to conceal the 
sequence until interventions 
were assigned
Implementation 10 Who generated the random 
allocation sequence, who 
enrolled participants, and who 
assigned participants to 
interventions
Blinding 11a If done, who was blinded after 
assignment to interventions 
(for example, participants, 
care providers, those 
assessing outcomes) and how
11b If relevant, description of the 
similarity of interventions
Statistical methods 12a Statistical methods used to 
compare groups for primary 
and secondary outcomes
12b Methods for additional 
analyses, such as subgroup 
analyses and adjusted 
analyses
Results
Participant flow (a diagram is 
strongly recommended)
13a For each group, the numbers 
of participants who were 
randomly assigned, received 
intended treatment, and were 
analysed for the primary 
outcome
13b For each group, losses and 
exclusions after 
randomisation, together with 
reasons
Recruitment 14a Dates defining the periods of 
recruitment and follow-up
14b Why the trial ended or was 
stopped
Baseline data 15 A table showing baseline 
demographic and clinical 
characteristics for each group
Numbers analysed 16 For each group, number of 
participants (denominator) 
included in each analysis and 
whether the analysis was by 
original assigned groups
Outcomes and estimation 17a For each primary and 
secondary outcome, results 
for each group, and the 
estimated effect size and its 
precision (such as 95% 
confidence interval)
Table 1: CONSORT 2010 checklist of information to include when reporting a randomised trial* (Continued)Schulz et al. BMC Medicine 2010, 8:18
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Background to CONSORT
Efforts to improve the reporting of randomised con-
trolled trials accelerated in the mid-1990s, spurred partly
by methodological research. Researchers had shown for
many years that authors reported such trials poorly, and
empirical evidence began to accumulate that some poorly
conducted or poorly reported aspects of trials were asso-
ciated with bias [14]. Two initiatives aimed at developing
reporting guidelines culminated in one of us (DM) and
Drummond Rennie organising the first CONSORT state-
ment in 1996 [5]. Further methodological research on
similar topics reinforced earlier findings [15] and fed into
the revision of 2001 [6-8]. Subsequently, the expanding
body of methodological research informed the refine-
ment of CONSORT 2010. More than 700 studies com-
prise the CONSORT database (located on the
CONSORT website), which provides the empirical evi-
dence to underpin the CONSORT initiative.
Indeed, CONSORT Group members continually moni-
tor the literature. Information gleaned from these efforts
provides an evidence base on which to update the CON-
SORT statement. We add, drop, or modify items based on
that evidence and the recommendations of the CON-
SORT Group, an international and eclectic group of clini-
cal trialists, statisticians, epidemiologists, and biomedical
editors. The CONSORT Executive (KFS, DGA, DM)
strives for a balance of established and emerging
researchers. The membership of the group is dynamic. As
our work expands in response to emerging projects and
needed expertise, we invite new members to contribute.
17b For binary outcomes, 
presentation of both absolute 
and relative effect sizes is 
recommended
Ancillary analyses 18 Results of any other analyses 
performed, including 
subgroup analyses and 
adjusted analyses, 
distinguishing pre-specified 
from exploratory
Harms 19 All important harms or 
unintended effects in each 
group (for specific guidance 
see CONSORT for harms [28])
Discussion
Limitations 20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if relevant, 
multiplicity of analyses
Generalisability 21 Generalisability (external 
validity, applicability) of the 
trial findings
Interpretation 22 Interpretation consistent with 
results, balancing benefits and 
harms, and considering other 
relevant evidence
Other information
Registration 23 Registration number and 
name of trial registry
Protocol 24 Where the full trial protocol 
can be accessed, if available
Funding 25 Sources of funding and other 
support (such as supply of 
drugs), role of funders
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration [13] for important 
clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials [11], non-inferiority 
and equivalence trials [12], non-pharmacological treatments [32], herbal interventions [33], and pragmatic trials [34]. Additional extensions 
are forthcoming: for those and for up to date references relevant to this checklist, see http://www.consort-statement.org.
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As such, CONSORT continually assimilates new ideas
and perspectives. That process informs the continually
evolving CONSORT statement.
Over time, CONSORT has garnered much support.
More than 400 journals, published around the world and
in many languages, have explicitly supported the CON-
SORT statement. Many other healthcare journals support
it without our knowledge. Moreover, thousands more
have implicitly supported it with the endorsement of the
CONSORT statement by the International Committee of
Medical Journal Editors http://www.icmje.org. Other
prominent editorial groups, the Council of Science Edi-
tors and the World Association of Medical Editors, offi-
cially support CONSORT. That support seems
warranted: when used by authors and journals, CON-
SORT seems to improve reporting [9].
Development of CONSORT 2010
Thirty one members of the CONSORT 2010 Group met
in Montebello, Canada, in January 2007 to update the
2001 CONSORT statement. In addition to the accumu-
lating evidence relating to existing checklist items, several
new issues had come to prominence since 2001. Some
participants were given primary responsibility for aggre-
gating and synthesising the relevant evidence on a partic-
ular checklist item of interest. Based on that evidence, the
group deliberated the value of each item. As in prior
CONSORT versions, we kept only those items deemed
absolutely fundamental to reporting a randomised con-
trolled trial. Moreover, an item may be fundamental to a
trial but not included, such as approval by an institutional
ethical review board, because funding bodies strictly
enforce ethical review and medical journals usually
address reporting ethical review in their instructions for
authors. Other items may seem desirable, such as report-
ing on whether on-site monitoring was done, but a lack of
empirical evidence or any consensus on their value cau-
tions against inclusion at this point. The CONSORT 2010
Statement thus addresses the minimum criteria, although
that should not deter authors from including other infor-
mation if they consider it important.
After the meeting, the CONSORT Executive convened
teleconferences and meetings to revise the checklist.
After seven major iterations, a revised checklist was dis-
tributed to the larger group for feedback. With that feed-
back, the executive met twice in person to consider all the
comments and to produce a penultimate version. That
served as the basis for writing the first draft of this paper,
Figure 1 Flow diagram of the progress through the phases of a parallel randomised trial of two groups (that is, enrolment, intervention 
allocation, follow-up, and data analysis).Schulz et al. BMC Medicine 2010, 8:18
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which was then distributed to the group for feedback.
After consideration of their comments, the executive fin-
alised the statement.
The CONSORT Executive then drafted an updated
explanation and elaboration manuscript, with assistance
from other members of the larger group. The substance
of the 2007 CONSORT meeting provided the material for
the update. The updated explanation and elaboration
manuscript was distributed to the entire group for addi-
tions, deletions, and changes. That final iterative process
converged to the CONSORT 2010 Explanation and Elab-
oration [13].
Changes in CONSORT 2010
The revision process resulted in evolutionary, not revolu-
tionary, changes to the checklist (Table 1), and the flow
diagram was not modified except for one word (Figure 1).
Moreover, because other reporting guidelines augment-
ing the checklist refer to item numbers, we kept the exist-
ing items under their previous item numbers except for
some renumbering of items 2 to 5. We added additional
items either as a sub-item under an existing item, an
entirely new item number at the end of the checklist, or
(with item 3) an interjected item into a renumbered seg-
ment. We have summarised the noteworthy general
changes in Appendix 1 and specific changes in Appendix
2. The CONSORT website contains a side by side com-
parison of the 2001 and 2010 versions.
Implications and limitations
We developed CONSORT 2010 to assist authors in writ-
ing reports of randomised controlled trials, editors and
peer reviewers in reviewing manuscripts for publication,
and readers in critically appraising published articles. The
CONSORT 2010 Explanation and Elaboration provides
elucidation and context to the checklist items. We
strongly recommend using the explanation and elabora-
tion in conjunction with the checklist to foster complete,
clear, and transparent reporting and aid appraisal of pub-
lished trial reports.
CONSORT 2010 focuses predominantly on the two
group, parallel randomised controlled trial, which
accounts for over half of trials in the literature [2]. Most
of the items from the CONSORT 2010 Statement, how-
ever, pertain to all types of randomised trials. Neverthe-
less, some types of trials or trial situations dictate the
need for additional information in the trial report. When
in doubt, authors, editors, and readers should consult the
CONSORT website for any CONSORT extensions,
expansions (amplifications), implementations, or other
guidance that may be relevant.
The evidence based approach we have used for CON-
SORT also served as a model for development of other
reporting guidelines, such as for reporting systematic
reviews and meta-analyses of studies evaluating interven-
tions [16], diagnostic studies [17], and observational stud-
ies [18]. The explicit goal of all these initiatives is to
improve reporting. The Enhancing the Quality and
Transparency of Health Research (EQUATOR) Network
will facilitate development of reporting guidelines and
help disseminate the guidelines: http://www.equator-net-
work.org provides information on all reporting guidelines
in health research.
With CONSORT 2010, we again intentionally declined
to produce a rigid structure for the reporting of ran-
domised trials. Indeed, SORT [19] tried a rigid format,
and it failed in a pilot run with an editor and authors [20].
Consequently, the format of articles should abide by jour-
nal style, editorial directions, the traditions of the
research field addressed, and, where possible, author
preferences. We do not wish to standardise the structure
of reporting. Authors should simply address checklist
items somewhere in the article, with ample detail and
lucidity. That stated, we think that manuscripts benefit
from frequent subheadings within the major sections,
especially the methods and results sections.
CONSORT urges completeness, clarity, and transpar-
ency of reporting, which simply reflects the actual trial
design and conduct. However, as a potential drawback, a
reporting guideline might encourage some authors to
report fictitiously the information suggested by the guid-
ance rather than what was actually done. Authors, peer
reviewers, and editors should vigilantly guard against that
potential drawback and refer, for example, to trial proto-
cols, to information on trial registers, and to regulatory
agency websites. Moreover, the CONSORT 2010 State-
ment does not include recommendations for designing
and conducting randomised trials. The items should elicit
clear pronouncements of how and what the authors did,
but do not contain any judgments on how and what the
authors should have done. Thus, CONSORT 2010 is not
intended as an instrument to evaluate the quality of a
trial. Nor is it appropriate to use the checklist to con-
struct a "quality score."
Nevertheless, we suggest that researchers begin trials
with their end publication in mind. Poor reporting allows
authors, intentionally or inadvertently, to escape scrutiny
of any weak aspects of their trials. However, with wide
adoption of CONSORT by journals and editorial groups,
m o s t  a u t h o r s  s h o u l d  h a v e  t o  r e p o r t  t r a n s p a r e n t l y  a l l
important aspects of their trial. The ensuing scrutiny
rewards well conducted trials and penalises poorly con-
ducted trials. Thus, investigators should understand the
CONSORT 2010 reporting guidelines before starting a
trial as a further incentive to design and conduct their tri-
als according to rigorous standards.
CONSORT 2010 supplants the prior version published
in 2001. Any support for the earlier version accumulatedSchulz et al. BMC Medicine 2010, 8:18
http://www.biomedcentral.com/1741-7015/8/18
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from journals or editorial groups will automatically
extend to this newer version, unless specifically requested
otherwise. Journals that do not currently support CON-
SORT may do so by registering on the CONSORT web-
site. If a journal supports or endorses CONSORT 2010, it
should cite one of the original versions of CONSORT
2010, the CONSORT 2010 Explanation and Elaboration,
and the CONSORT website in their "Instructions to
authors." We suggest that authors who wish to cite CON-
SORT should cite this or another of the original journal
versions of CONSORT 2010 Statement, and, if appropri-
ate, the CONSORT 2010 Explanation and Elaboration
[13]. All CONSORT material can be accessed through the
original publishing journals or the CONSORT website.
Groups or individuals who desire to translate the CON-
SORT 2010 Statement into other languages should first
consult the CONSORT policy statement on the website.
We emphasise that CONSORT 2010 represents an
evolving guideline. It requires perpetual reappraisal and,
if necessary, modifications. In the future we will further
revise the CONSORT material considering comments,
criticisms, experiences, and accumulating new evidence.
We invite readers to submit recommendations via the
CONSORT website.
Appendix 1: Noteworthy general changes in 
CONSORT 2010 Statement
• We simplified and clarified the wording, such as in
items 1, 8, 10, 13, 15, 16, 18, 19, and 21
• We improved consistency of style across the items by
removing the imperative verbs that were in the 2001 ver-
sion
• We enhanced specificity of appraisal by breaking
some items into sub-items. Many journals expect authors
to complete a CONSORT checklist indicating where in
the manuscript the items have been addressed. Experi-
ence with the checklist noted pragmatic difficulties when
an item comprised multiple elements. For example, item
4 addresses eligibility of participants and the settings and
locations of data collection. With the 2001 version, an
author could provide a page number for that item on the
checklist, but might have reported only eligibility in the
paper, for example, and not reported the settings and
locations. CONSORT 2010 relieves obfuscations and
forces authors to provide page numbers in the checklist
for both eligibility and settings.
Appendix 2: Noteworthy specific changes in 
CONSORT 2010 Statement
Item 1b (title and abstract)-We added a sub-item on pro-
viding a structured summary of trial design, methods,
results, and conclusions and referenced the CONSORT
for abstracts article [21].
Item 2b (introduction)-We added a new sub-item (for-
merly item 5 in CONSORT 2001) on "Specific objectives
or hypotheses"
Item 3a (trial design)-We added a new item including
this sub-item to clarify the basic trial design (such as par-
allel group, crossover, cluster) and the allocation ratio
Item 3b (trial design)-We added a new sub-item that
addresses any important changes to methods after trial
commencement, with a discussion of reasons
Item 4 (participants)-Formerly item 3 in CONSORT
2001
Item 5 (interventions)-Formerly item 4 in CONSORT
2001. We encouraged greater specificity by stating that
descriptions of interventions should include "sufficient
details to allow replication"[3]
Item 6 (outcomes)-We added a sub-item on identifying
any changes to the primary and secondary outcome (end-
point) measures after the trial started. This followed from
empirical evidence that authors frequently provide analy-
ses of outcomes in their published papers that were not
the prespecified primary and secondary outcomes in
their protocols, while ignoring their prespecified out-
comes (that is, selective outcome reporting) [4,22]. We
eliminated text on any methods used to enhance the qual-
ity of measurements
Item 9 (allocation concealment mechanism)-We
reworded this to include mechanism in both the report
topic and the descriptor to reinforce that authors should
report the actual steps taken to ensure allocation conceal-
ment rather than simply report imprecise, perhaps banal,
assurances of concealment
Item 11 (blinding)-We added the specification of how
blinding was done and, if relevant, a description of the
similarity of interventions and procedures. We also elimi-
nated text on "how the success of blinding (masking) was
assessed" because of a lack of empirical evidence support-
ing the practice as well as theoretical concerns about the
validity of any such assessment [23,24]
Item 12a (statistical methods)-We added that statistical
methods should also be provided for analysis of second-
ary outcomes
Sub-item 14b (recruitment)-Based on empirical
research, we added a sub-item on "Why the trial ended or
was stopped" [25]
Item 15 (baseline data)-We specified "A table" to clarify
that baseline and clinical characteristics of each group are
most clearly expressed in a table
Item 16 (numbers analysed)-We replaced mention of
"intention to treat" analysis, a widely misused term, by a
more explicit request for information about retaining
participants in their original assigned groups [26]
Sub-item 17b (outcomes and estimation)-For appropri-
ate clinical interpretability, prevailing experience sug-
gested the addition of "For binary outcomes, presentationSchulz et al. BMC Medicine 2010, 8:18
http://www.biomedcentral.com/1741-7015/8/18
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of both relative and absolute effect sizes is recommended"
[27]
Item 19 (harms)-We included a reference to the CON-
SORT paper on harms [28]
Item 20 (limitations)-We changed the topic from "Inter-
pretation" and supplanted the prior text with a sentence
focusing on the reporting of sources of potential bias and
imprecision
Item 22 (interpretation)-We changed the topic from
"Overall evidence." Indeed, we understand that authors
should be allowed leeway for interpretation under this
nebulous heading. However, the CONSORT Group
expressed concerns that conclusions in papers frequently
misrepresented the actual analytical results and that
harms were ignored or marginalised. Therefore, we
changed the checklist item to include the concepts of
results matching interpretations and of benefits being
balanced with harms
Item 23 (registration)-We added a new item on trial reg-
istration. Empirical evidence supports the need for trial
registration, and recent requirements by journal editors
have fostered compliance [29]
Item 24 (protocol)-We added a new item on availability
of the trial protocol. Empirical evidence suggests that
authors often ignore, in the conduct and reporting of
their trial, what they stated in the protocol [4,22]. Hence,
availability of the protocol can instigate adherence to the
protocol before publication and facilitate assessment of
adherence after publication
Item 25 (funding)-We added a new item on funding.
Empirical evidence points toward funding source some-
times being associated with estimatedeatment effects [30]
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